Your location:Home page > Program
Joseph Tam
Share the:
The Hebrew University of Jerusalem | Pharmacology

Prof. Joseph (Yossi) Tam received his B.Med.Sc., M.Sc., Ph.D. and D.M.D. from the Hebrew

University of Jerusalem. He did his postdoctoral training at the National Institutes of Health

(NIH), and in 2014, Prof. Tam moved to the Hebrew University, where he heads the Obesity and

Metabolism Laboratory at the Institute for Drug Research, and focuses on targeting the

endocannabinoid (eCB) system for Obesity, Diabetes and the metabolic syndrome. Prof. Tam

serves as the Director of the Hebrew University’s Multidisciplinary Center for Cannabinoid Research

(MCCR). He is the Past-President of the International Cannabinoid Research Society (ICRS), and a

Scientific Advisory Board Member of several biotech companies, which develop a portfolio of

non-psychoactive cannabinoid and cannabinoid-modulating medicines for unmet market needs.

He won major national and international grants, authored over 60 peer-reviewed papers in

leading journals, and three book chapters, and he is a co-inventor of 13 patents; most of which

have been licensed to different biotech companies for future development. Prof. Tam also won

many prizes and awards, such as The Chowers Award by The Israeli Endocrine Society, The Sir

Zelman Cowen Universities Fund (SZCUF) Prize for Discovery in Medical Research in the field

of Metabolism and Obesity, and the prestigious US NCATS Director's Award by the National

Institutes of Health. For his groundbreaking research in the cannabinoid filed, Prof. Tam won the

2019 William Devane Young Investigator Award by the ICRS, and 2020 Hebrew University's

Rector Excellence Award for an Outstanding Scientist.

Attendance records:1

The lecture video:0





The academic assignments are as follows
Date (UTC+8) Time (UTC+8) Local Time Hall Session Role Talk Title
2022-06-17 11:30-11:45 2022-06-17,11:30-11:45Hall 2

Dyslipidemia, Obesity and Metabolic Syndrome in Kidney Disease - Session 29

Speaker Targeting Renal Cannabinoid-1 Receptor for the Treatment of Diabesity-induced CKD